Assessing the state of Medicaid coverage for gene and cell therapies

Abstract

Gene and cell therapies differ from small-molecule therapeutics in many ways, including the potential to treat the underlying cause of disease with a one-time dosing regimen. Those characteristics make gene and cell therapies highly valuable additions to the healthcare arsenal. However, one-time durable therapies currently come with associated upfront costs that can pose challenges to the US healthcare system, which is designed to support chronic treatments and care. The accessibility of such therapies to patients is of paramount importance to the American Society of Gene and Cell Therapy (ASGCT), which represents over 4,800 researchers, scientists, and clinicians in the field with the core mission of advancing the discovery and clinical application of genetic and cellular therapies to alleviate human disease.